Key result
MFAP4 deletion attenuated Angiotensin II-induced left atrial fibrosis and decreased susceptibility to atrial fibrillation compared with wild-type mice.
Why the study?
Although MFAP4 is associated with AF, its specific role and underlying mechanism in atrial fibrosis remain undefined.
Does MFAP4 deletion prevent angiotensin II-induced atrial fibrosis and atrial fibrillation in mice?
Population
MFAP4 knockout (MFAP4-KO) mice and wild-type (WT) littermates
Comparison
MFAP4-KO vs WT littermates receiving angiotensin II (2000 ng/kg/min for 3 weeks)
Design
Preclinical animal study
Follow-up
3 weeks
Authors
Loading...
MFAP4 merits target validation in AF models; leaves open human therapeutic translation.
Does MFAP4 deletion prevent angiotensin II-induced atrial fibrosis and atrial fibrillation in mice?
MFAP4 deletion attenuates angiotensin II-induced atrial fibrosis and susceptibility to atrial fibrillation, suggesting MFAP4 as a potential therapeutic target.
Wang et al. (2021) studied Atrial fibrosis and atrial fibrillation. MFAP4 deletion vs. Wild-type (WT) littermates was evaluated on Atrial fibrosis and susceptibility to atrial fibrillation. MFAP4 deletion attenuated Angiotensin II-induced left atrial fibrosis and decreased susceptibility to atrial fibrillation compared with wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: